Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised
What is established Cejemly (active substance: sugemalimab) is a medication authorized by the European Medicines Agency (EMA) for the treatment of non-small cell lung cancer (NSCLC) in adults. It is indicated specifically for: Patients with metastatic NSCLC lacking genetic mutations in EGFR, ALK, ROS1, or RET genes, used in combination with platinum-based…
Protect yourself and others during the cold season
Evidence Dossier: Protecting Against Respiratory Infections During the Cold Season in Europe What is established Respiratory infections such as influenza, respiratory syncytial virus (RSV), COVID-19, and pneumococcal disease pose significant health challenges in Europe, especially during colder months. These infections are known to lead to serious illness, particularly in vulnerable populations including…
Respiratory infections season
What is established As Europe enters the colder months, respiratory infections commonly see an increase in incidence. Key respiratory pathogens involved are influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and bacteria causing pneumococcal disease. These infections can lead to serious illness, particularly among vulnerable populations such as the elderly, young children,…
Seeing the invisible: Reorienting cardiovascular risk prediction across the disease trajectory
What is established Cardiovascular risk prediction has been a central component of preventive medicine for decades. Traditional risk equations such as the Framingham model, Pooled Cohort Equations, SCORE2, QRISK4, PREDICT, and China-PAR estimate an individual’s absolute risk of cardiovascular events over periods generally ranging from 5 to 30 years. These models utilize…
Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 11, Status: Authorised
What is established Vyvgart (efgartigimod alfa) is an authorised medicine in the European Union for adults with two rare neuromuscular autoimmune disorders: generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Both diseases involve an abnormal immune response where autoantibodies attack essential components of muscle or nerve cells, leading to weakness…
Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Date of authorisation: 20/10/1995, Revision: 28, Status: Authorised
What is established GONAL-f, containing the active substance follitropin alfa, is a medicine authorised in the European Union since 1995. It is manufactured by Merck Serono Europe Ltd and is used primarily in fertility treatments. Follitropin alfa is a recombinant form of the natural hormone follicle-stimulating hormone (FSH). In women, FSH stimulates…
Plasma proteomic signatures of subclinical atherosclerosis progression for cardiovascular risk stratification: A cohort study
What is established Atherosclerosis, a condition characterized by the buildup of plaques in arterial walls, is a major underlying cause of cardiovascular diseases (CVD), including heart attacks and strokes. Traditional risk assessments for cardiovascular disease typically incorporate factors such as age, cholesterol levels, blood pressure, smoking status, and diabetes prevalence to predict…
Human medicines European public assessment report (EPAR): Darunavir Viatris (previously Darunavir Mylan), darunavir, Date of authorisation: 03/01/2017, Revision: 19, Status: Authorised
Evidence Dossier on Darunavir Viatris for HIV Treatment What is Established Darunavir Viatris is a generic antiviral medication authorized in the European Union for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It contains the active substance darunavir, a protease inhibitor that interferes with an enzyme essential for HIV reproduction,…
Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 7, Status: Authorised
What is established Imuldosa, containing the active substance ustekinumab, is a biologic medicine authorised by the European Medicines Agency (EMA) as of December 12, 2024. It is classified as a biosimilar to Stelara, meaning it is highly similar in structure, purity, and biological activity to this already authorised medicine. Imuldosa is approved…
The CBI-M framework for characterization of traumatic brain injury: Evaluation of performance using data from the CENTER-TBI and TRACK-TBI prospective cohort studies
The CBI-M Framework for Traumatic Brain Injury Characterization: An Evidence Dossier What is established Traumatic brain injury (TBI) is recognized as a complex, heterogeneous condition traditionally classified by clinical severity into mild, moderate, or severe categories. This conventional classification guides clinical management but is acknowledged to insufficiently capture underlying biological and clinical…